R. Manges

发表

A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

P. Sonneveld, S. Jagannath, A. Krishnan, 2013, British journal of haematology.

A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM).

P. Sonneveld, S. Jagannath, P. Voorhees, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma

R. Rifkin, A. Cartmell, J. Berenson, 2017, American journal of hematology.

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

S. Jagannath, R. Vij, J. Kaufman, 2015, Clinical lymphoma, myeloma & leukemia.

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

J. Nemunaitis, H. Hurwitz, Z. Wainberg, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.

P. Philip, A. Santoro, P. Karásek, 2013, European journal of cancer.

Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

R. Greil, U. Jäger, L. Trümper, 2021, International Journal of Hematology.

Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients.

J. Reeves, I. Flinn, R. Neuwirth, 2009 .

Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma

J. Rossi, P. Sonneveld, S. Jagannath, 2007 .

A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,

P. Sonneveld, S. Jagannath, A. Krishnan, 2011 .

A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).

Nikhil Uppal, Jason Clark, Philip J. Stella, 2014 .

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

S. Jagannath, R. Vij, J. Kaufman, 2014 .

Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.

R. Greil, U. Jäger, L. Trümper, 2019, Journal of Clinical Oncology.

APRICoT-P: A phase II randomized placebo controlled study of apricoxib, a potent COX-2 inhibitor in combination with erlotinib and gemcitabine in pancreatic cancer patients.

R. Langdon, S. Zaknoen, P. Stella, 2010 .